Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2015-10-26 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
2015年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of 葵花药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as balance sheets, income statements, cash flow statements, shareholder information, and management commentary on financial performance and changes during the quarter. The document includes actual financial statements and substantive financial data for the third quarter of 2015. It is not a brief announcement or a certification letter, but a comprehensive interim report covering a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-10-26 Chinese
2015年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2015 Third Quarter Report" of 葵花药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, cash flow, shareholder information, and management commentary on financial performance and business activities for the third quarter of 2015. The length of the document (over 12,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim/quarterly report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2015
2015-10-26 Chinese
关于收购吉林省健今药业有限责任公司股权之可行性研究报告
M&A Activity Classification · 95% confidence The document is a detailed feasibility study report regarding the acquisition of a pharmaceutical company (吉林省健今药业有限责任公司) by 葵花药业集团股份有限公司. It includes sections on project introduction, shareholding structure, business overview, financial status, acquisition scheme, financial evaluation, and risk analysis. The content focuses on the proposed merger/acquisition, valuation, financial forecasts, and strategic rationale for the acquisition. There is no indication that this is an announcement or a brief summary; it is a comprehensive report on the acquisition project. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids.
2015-10-16 Chinese
吉林省健今药业有限责任公司审计报告
Regulatory Filings
2015-10-16 Chinese
拟收购吉林建今药业有限责任公司股权评估项目评估报告
Regulatory Filings
2015-10-16 Chinese
独立董事关于第二届董事会第二十四次会议相关议案之独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several board meeting proposals, including the reappointment of the financial audit firm, changes in the use of raised funds, and entrusted loans to a subsidiary. It references the second session of the board's 24th meeting and discusses compliance with company articles and laws. The content focuses on governance and board-level decisions rather than full financial statements or audit reports. The document length is short (1732 characters) and does not contain detailed financial data or audit results, but rather opinions and approvals related to board proposals. This fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to board or senior management decisions.
2015-10-15 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.